原始来源记录
决策级顶线结果
AVTX-009 2期LOTUS试验在HS：预计2026年Q2公布顶线数据
Avalo已完成AVTX-009在化脓性汗腺炎中的2期LOTUS试验入组。顶线结果现指引为2026年Q2，为该资产确立下一个监管/临床里程碑。
关键事实
来源摘录
EX-99.1 2 ex-991_dec2025xavalocorp.htm EX-99.1 ex-991_dec2025xavalocorp ne mission. Advancing an inspired pipeline of novel IL-1β therapies focused on treating unmet medical needs. CORPORATE OVERVIEW December 2025 | AVALO THERAPEUTICS, INC. (AVTX) Exhibit 99.1 Forward-Looking Statements This presentation may include forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to significant risks and uncertainties that are subject to change based on various factors (many of which are beyond Avalo’s control), which could cause actual results to differ from the forward-looking statements. Such statements may include, without limitation,